How long does HRT take to work? What the guidelines say about timing

When hormone therapy starts, or a dose changes, the obvious question is how long before you can tell whether it is working. Online answers often come as a precise week-by-week schedule. The guidelines are more modest: they give a review point, a window in which side effects usually settle, and a window in which bleeding is expected.

This article describes what that guidance says. It is not advice about your own treatment, which is a conversation for you and the clinician who prescribes it.

The short version

NICE recommends reviewing each treatment at three months to assess how well it is working and how well it is tolerated, then once a year, unless there is a reason for an earlier review such as the treatment not working, side effects or adverse events ¹. The NHS describes the same pattern: a GP will usually recommend a review three months after you start HRT, or if you change your type of HRT ².

Three months is therefore where a structured judgement is usually made. It is not a promise that nothing changes before then, and it is not a rule that a problem has to wait that long.

What the guidelines say about effect

The Menopause Society describes hormone therapy as the most effective treatment for vasomotor symptoms, meaning hot flushes and night sweats, and for the genitourinary syndrome of menopause ⁴.

Neither it nor NICE sets out a standard number of weeks for each symptom to improve. Schedules that do are usually built from averages in particular trials, and averages say little about how one person will respond.

What the guidance does make clear is that symptoms do not all respond in the same way. Genitourinary symptoms such as vaginal dryness are often treated separately: NICE recommends offering vaginal oestrogen to people with these symptoms, including people already using systemic HRT ¹. The guide to vaginal dryness and GSM on this site covers that in more detail.

Side effects in the early months

The NHS lists possible side effects of the oestrogen in HRT, including breast tenderness, unexpected vaginal bleeding or spotting, feeling sick, mood changes, leg cramps and mild rash or itching, and says these will often go away after a few weeks. It says the same of side effects from the progestogen ³.

Overall, the NHS describes side effects as usually mild and passing within three months of starting treatment ². Because they usually improve over time, it says it is a good idea to carry on with treatment for at least three months if possible ³. Decisions about stopping, switching or changing a dose sit with the prescriber, and NICE allows for an earlier review when side effects are a problem ¹.

Bleeding on HRT

This is the timing question with the clearest guidance.

NICE tells clinicians to explain that vaginal bleeding is a common side effect during the first six months of systemic HRT, or within any three months of changing the dose or preparation, and that people should seek medical help promptly if unscheduled bleeding happens outside those timeframes ¹.

The NHS says irregular bleeding or spotting is common in the first few months after starting HRT, usually settles within six months and is not usually a sign of anything serious. On continuous combined HRT it is common in the first four to six months. It suggests telling a GP at the first review after three months if irregular bleeding is happening ³.

Get checked: bleeding outside the expected windows

NICE advises seeking medical help promptly for unscheduled vaginal bleeding beyond the first six months of systemic HRT, or beyond three months after a change of dose or preparation ¹. The guide to irregular bleeding on this site sets out the other bleeding changes that need checking.

When an earlier review happens

NICE names the grounds for reviewing before three months: the treatment not working, side effects, or adverse events ¹. It also recommends referral to a healthcare professional with expertise in menopause if treatments do not improve symptoms or side effects continue ¹.

Guidance in the US and Europe

In the US, The Menopause Society says treatment should be individualised, with periodic reassessment of the benefits and risks of continuing, and that longer use should be for documented reasons such as persistent hot flashes, decided together with a clinician ⁴. The FDA advises starting systemic hormone therapy within 10 years of menopause onset or before 60 ⁵.

In Europe, the European Menopause and Andropause Society (EMAS) says treatment should be individualised to age, symptom severity, personal and family risk, other conditions and preference ⁶.

What is still uncertain

There is no reliable way to predict in advance how quickly one person will respond, or which symptoms will change first.

Guidelines also say little about how long to stay with a treatment that is partly working. That judgement is made between you and your clinician, and it is easier when the months in between have been written down.

Keeping a record between reviews

A review at three months relies on someone being able to describe three months. The useful facts are dates and counts: the day a treatment started or changed, how often the main symptoms happened each week, any side effects with the week they appeared, and any bleeding.

A notebook does that job. Halcyon puts symptoms and every dose change on one timeline and prints a one-page summary for the review, if you would rather keep it on your phone.